What Is Diamond-Blackfan Anemia? Symptoms & Treatment

Diamond-Blackfan anemia (DBA) is a rare inherited bone marrow failure syndrome in which the body fails to produce enough red blood cells. It affects roughly 7 out of every million live births and usually shows up within the first year of life, often as severe anemia that does not improve on its own. What makes DBA unusual among childhood anemias is that it reaches far beyond the blood: about half of those affected also have birth defects involving the head, hands, heart, or urinary tract, and the condition carries a lifelong elevated risk of certain cancers.

How DBA Develops

At its root, DBA is a problem with ribosomes, the molecular machinery inside every cell that builds proteins. In most patients, a mutation in one of the genes coding for ribosomal proteins disrupts normal ribosome assembly. That disruption triggers a stress response inside the cell nucleus that activates a tumor-suppressor protein called p53, which in turn pushes developing red blood cells toward self-destruction or growth arrest.

The result is a near-absence of the earliest red blood cell precursors in the bone marrow, a feature called erythroblastopenia. Researchers have confirmed that the developmental block happens early, between two immature stages of red blood cell formation, so very few mature red blood cells ever make it into the bloodstream.

To date, mutations in about 20 different ribosomal protein genes have been linked to DBA, and together these account for roughly half of all cases.¹ In a smaller number of patients, the cause is not a ribosomal protein gene at all. Researchers identified mutations in GATA1, a gene encoding a transcription factor critical for red blood cell development, proving that the reduction in red blood cell production in DBA can arise from causes other than ribosomal defects.² For the remaining patients with no identifiable mutation, the genetic basis is still unknown.

How It Is Inherited

Most DBA cases follow an autosomal dominant pattern, meaning a single copy of the mutated gene is enough to cause the disorder. About 40 to 45 percent of cases are inherited from a parent who carries the mutation, while the rest arise as new (de novo) mutations in the child. One complication for families is that DBA shows variable expressivity and incomplete penetrance: a parent and child can carry the exact same mutation yet have very different disease severity, and some carriers have no symptoms at all.³ This makes genetic counseling tricky, because a family member with a “silent” mutation could still pass on a clinically significant form of the disease to their children.

Recognizing the Symptoms

The hallmark symptom is anemia, typically noticed in the first few months of life. Infants look pale, tire easily during feeding, and may have a rapid heart rate. Blood tests show low hemoglobin with unusually large red blood cells (macrocytic anemia) and an extremely low reticulocyte count, meaning the bone marrow is barely releasing any new red blood cells.⁴ About a quarter of patients are diagnosed at birth or within the first week, and most are diagnosed before their first birthday.

Beyond the anemia, physical abnormalities are common. Estimates of how many patients have congenital malformations range from about 30 to 50 percent in large registries, though a recent detailed evaluation that included imaging and careful physical exams found dysmorphic features in close to 90 percent of patients when subtle findings were counted.⁵ That gap suggests milder features are frequently missed if nobody is specifically looking for them.

The most commonly affected areas include:

Head and face: craniofacial differences such as a small jaw, a high-arched palate, wide-set eyes, a flat midface, or a cleft lip/palate. Roughly three-quarters of patients in one detailed study had at least one craniofacial finding.⁵
Hands and thumbs: abnormalities of the thumb (small, absent, or extra-jointed) or other finger differences appear in roughly a third of patients.
Heart and kidneys: structural heart defects and urogenital tract abnormalities occur in a smaller but significant fraction.
Growth: short stature is a common feature of DBA itself, though it can be worsened by long-term steroid treatment.

Specific ribosomal protein gene mutations tend to correlate with specific malformation patterns. Mutations in RPL5 and RPL11, for instance, are more strongly associated with craniofacial and thumb abnormalities than mutations in other genes.⁶

Making the Diagnosis

Diagnosing DBA involves piecing together the clinical picture (early-onset anemia, low reticulocytes, possible birth defects) with laboratory and genetic testing. A bone marrow biopsy typically reveals a near-complete absence of red blood cell precursors while the rest of the marrow looks normal, which helps distinguish DBA from other causes of bone marrow failure.

One particularly useful lab marker is erythrocyte adenosine deaminase (eADA). Patients with DBA tend to have levels about three to four times higher than normal. A landmark study found that mean eADA in DBA patients was roughly 2.2 units per gram of hemoglobin, compared with 0.62 in healthy controls, and that this elevation was not seen in other childhood anemias or bone marrow failure syndromes.⁷ More recent work confirmed its diagnostic power, finding sensitivity around 84 percent and specificity around 95 percent when comparing DBA to other marrow failure conditions.⁸

A normal eADA level does not completely rule out DBA, however. Patients with GATA1 mutations, for example, may have normal eADA levels, so the test works best as a supporting clue rather than a standalone diagnostic.⁹ Genetic testing for known DBA-associated genes is increasingly used to confirm the diagnosis, though it will not identify every case since about half of patients have no detectable mutation in a known gene.

The main condition doctors need to distinguish DBA from is transient erythroblastopenia of childhood (TEC), a self-limited condition that also causes a temporary drop in red blood cell production. TEC usually appears after 12 months of age, resolves on its own, and does not come with congenital anomalies or elevated eADA, which helps separate the two.

Treatment With Corticosteroids

Corticosteroids, usually prednisone, remain the standard first-line therapy for DBA and have been for decades. How they improve red blood cell production in DBA is still not fully understood, but about 80 percent of patients respond initially. The catch is that the response varies widely. Some patients maintain remission on a low dose, others need doses high enough to cause serious side effects, and some stop responding over time.¹⁰

The side effects of long-term steroid use are a significant burden, especially in growing children. Growth suppression, weakened bones, high blood sugar, weight gain, mood changes, and susceptibility to infections are all well-documented consequences. Because of this, doctors generally aim to find the lowest steroid dose that keeps hemoglobin at an acceptable level, and treatment is typically avoided entirely in infants under one year because the growth effects are particularly damaging at that age.

Chronic Transfusions and Iron Overload

Patients who do not respond to steroids, or whose side effects are intolerable, shift to a regimen of regular red blood cell transfusions, usually every three to five weeks. Transfusions are effective at keeping hemoglobin levels stable, but each unit of blood carries a load of iron that the body has no efficient way to excrete. Over months and years, this iron accumulates in the liver, heart, and endocrine organs.

Transfusion-dependent DBA patients develop iron overload rapidly and face a meaningful risk of cardiac complications as a result.¹¹ To counteract this, most transfusion-dependent patients need iron chelation therapy, which uses drugs that bind excess iron and allow it to be removed from the body through urine or stool. Chelation is a daily or near-daily commitment and can itself cause side effects including gastrointestinal discomfort and kidney or liver changes, but left untreated, iron overload can lead to heart failure, liver cirrhosis, and endocrine problems like diabetes or delayed puberty.

Stem Cell Transplantation

The only established cure for the blood-related aspects of DBA is an allogeneic hematopoietic stem cell transplant, in which a donor’s marrow replaces the patient’s defective one. A large retrospective European study reported three-year overall survival around 84 percent for transplanted DBA patients.¹² Transplant is generally reserved for patients who are transfusion-dependent, especially younger patients, because outcomes tend to be better when transplant is performed early, before iron overload has caused organ damage.¹³

The decision to transplant is complex. Transplant carries real risks of its own, including graft-versus-host disease, infection, and organ toxicity from the conditioning chemotherapy. It requires a suitable donor, ideally a matched sibling. When no matched sibling is available, matched unrelated donors or other alternatives are used, though outcomes are somewhat less favorable. Transplant also corrects only the hematologic features of DBA; it does not reverse congenital malformations or eliminate the underlying cancer predisposition in non-blood tissues.

Experimental Approaches

Several newer strategies are being explored. L-leucine, an amino acid that stimulates protein synthesis through a different cellular pathway, has shown promise in a small pilot study. In that trial, two of the participants achieved a complete response, meaning they became transfusion-independent. One was a nine-year-old boy who had never responded to steroids and had required transfusions since infancy; after starting L-leucine, he received his last transfusion within a month and was still maintaining normal hemoglobin levels three years later.¹⁴ These results are encouraging but come from a very small study, and larger trials are needed before L-leucine can be considered a standard option.

Gene therapy is another area of active research. The logic is straightforward: if the disease is caused by having only one functional copy of a ribosomal protein gene, adding a working copy back into the patient’s own stem cells should fix the defect. Early preclinical work using gene-editing tools has shown that disrupting the same gene (RPS19) that is mutated in many DBA patients recreates the characteristic block in red blood cell development in lab models, confirming that the target is correct.¹⁵ Clinical gene therapy trials for DBA are in early stages.

Spontaneous Remission

One of the more puzzling aspects of DBA is that roughly 20 percent of patients eventually go into spontaneous remission, meaning their hemoglobin stabilizes without any treatment. This typically happens during the first decade of life, though it has been reported in adults as well. Nobody fully understands why some patients remit and others do not. Remission is not always permanent, either. Stresses such as pregnancy, infection, or surgery can trigger relapse in people who have been off treatment for years.

Cancer Risk

DBA is recognized as a cancer predisposition syndrome. Data from the Diamond Blackfan Anemia Registry of North America, tracking over 600 patients across thousands of person-years, found that overall cancer incidence was about five times higher than expected for the general population. The risk was especially elevated for specific cancers: myelodysplastic syndrome, acute myeloid leukemia, colon cancer, osteogenic sarcoma (a bone cancer), and female genital cancers all occurred at rates far above what would normally be seen.¹⁶

What stands out is that the most common solid tumor in DBA patients is colorectal cancer, and it tends to appear at a much younger age than in the general population. Osteogenic sarcoma is the most common solid tumor among DBA patients in childhood and adolescence.¹⁷ These findings have led to growing discussions about whether DBA patients should undergo earlier and more frequent cancer screening than the general population, though formal screening guidelines specific to DBA have not yet been established.

Pregnancy in Women With DBA

Pregnancy is a recognized high-risk period for women with DBA. Even women who are in remission can relapse during pregnancy, and registry data paint a sobering picture: of 50 reported pregnancies in DBA patients, only 60 percent resulted in live births. About 43 percent of those live births were preterm, compared with about 12 percent in the general population. Miscarriage rates were also elevated, and complications like placental abruption were several times more common than expected.¹⁸ Over half of women needed transfusions during pregnancy, and every steroid-dependent woman in the registry required transfusion support during pregnancy.¹⁹ Preconception counseling and close monitoring by both a hematologist and a maternal-fetal medicine specialist are considered essential.

Growing Up and Growing Older With DBA

Because DBA was historically viewed primarily as a pediatric disease, the adult experience has received less attention. But the reality is that DBA is a lifelong condition, and the transition from pediatric to adult care is often rocky. Adult patients deal with the cumulative effects of decades of treatment: iron overload affecting the heart and liver, steroid-related bone thinning and metabolic changes, and the psychological toll of managing a chronic rare disease.²⁰

Registry data suggest a median survival of about 56 years, which is considerably shorter than the general population’s life expectancy.¹⁶ The causes of death in adulthood are split among complications of iron overload, cancer, infections, and transplant-related complications. Many adult hematologists have limited experience with DBA simply because it is so rare, and coordinated multidisciplinary care covering hematology, cardiology, endocrinology, and cancer surveillance remains the exception rather than the norm. Advocacy groups and patient registries have become increasingly important for connecting patients with experienced specialists and pushing for standardized adult care guidelines.